{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:18:22Z","timestamp":1775837902889,"version":"3.50.1"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Telavancin is a bactericidal, semisynthetic lipoglycopeptide indicated in the United States for the treatment of complicated skin and skin structure infections caused by susceptible Gram-positive bacteria and is under investigation as a once-daily treatment for nosocomial pneumonia. The related\n            <jats:italic>vanA<\/jats:italic>\n            and\n            <jats:italic>vanB<\/jats:italic>\n            gene clusters mediate acquired resistance to glycopeptides in enterococci by remodeling the dipeptide termini of peptidoglycan precursors from\n            <jats:sc>d<\/jats:sc>\n            -alanyl-\n            <jats:sc>d<\/jats:sc>\n            -alanine (\n            <jats:sc>d<\/jats:sc>\n            -Ala-\n            <jats:sc>d<\/jats:sc>\n            -Ala) to\n            <jats:sc>d<\/jats:sc>\n            -alanyl-\n            <jats:sc>d<\/jats:sc>\n            -lactate (\n            <jats:sc>d<\/jats:sc>\n            -Ala-\n            <jats:sc>d<\/jats:sc>\n            -Lac). In this study, we assessed the ability of telavancin to induce the expression of\n            <jats:italic>van<\/jats:italic>\n            genes in VanA- and VanB-type strains of vancomycin-resistant enterococci. Vancomycin, teicoplanin, and telavancin efficiently induced VanX activity in VanA-type strains, while VanX activity in VanB-type isolates was inducible by vancomycin but not by teicoplanin or telavancin. In VanA-type strains treated with vancomycin or telavancin, high levels of\n            <jats:sc>d<\/jats:sc>\n            -Ala-\n            <jats:sc>d<\/jats:sc>\n            -Lac-containing pentadepsipeptide were measured, while\n            <jats:sc>d<\/jats:sc>\n            -Ala-\n            <jats:sc>d<\/jats:sc>\n            -Ala pentapeptide was present at very low levels or not detected at all. In VanB-type strains, vancomycin but not telavancin induced high levels of pentadepsipeptide, while pentapeptide was not detected. Although vancomycin, teicoplanin, and telavancin induced similar levels of VanX activity in VanA-type strains, these organisms were more sensitive to telavancin, which displayed MIC values that were 32- and 128-fold lower than those of vancomycin and teicoplanin, respectively.\n          <\/jats:p>","DOI":"10.1128\/aac.01737-09","type":"journal-article","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T03:30:18Z","timestamp":1271734218000},"page":"2814-2818","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Specificity of Induction of the\n            <i>vanA<\/i>\n            and\n            <i>vanB<\/i>\n            Operons in Vancomycin-Resistant Enterococci by Telavancin"],"prefix":"10.1128","volume":"54","author":[{"given":"Craig M.","family":"Hill","sequence":"first","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Krause","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey R.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanne","family":"Blais","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bret M.","family":"Benton","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathai","family":"Mammen","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick P.","family":"Humphrey","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Kinana","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Unite\u0301 des Agents Antibacte\u0301riens, 75724 Paris Cedex 15, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Janc","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3011.2003.00072.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1996.00617.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.174.8.2582-2591.1992"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.175.1.117-127.1993"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2291"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.38.100184.002011"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00107a007"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80115-X"},{"key":"e_1_3_2_10_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2006"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00430441"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00015-06"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja026342h"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01641-07"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn124"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.178.5.1302-1309.1996"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01398-07"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1992.tb05314.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1220"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1994.tb00497.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(00)00186-4"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01737-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01737-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:21:30Z","timestamp":1645474890000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01737-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1128\/AAC.01737-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.01737-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"2009-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}